[Reactivity and immunologic activity of polyvalent split influenza vaccine in children].
Identifieur interne : 002064 ( Main/Curation ); précédent : 002063; suivant : 002065[Reactivity and immunologic activity of polyvalent split influenza vaccine in children].
Auteurs : H. Závadová [République tchèque] ; E. Domorázková ; J. Skovránková ; M. Vodicková ; P. Ragac ; V. VonkaSource :
- Ceskoslovenska pediatrie [ 0069-2328 ] ; 1990.
Descripteurs français
- KwdFr :
- Adolescent, Anticorps antiviraux (analyse), Calendrier vaccinal, Enfant, Enfant d'âge préscolaire, Humains, Nourrisson, Sialidase (pharmacologie), Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- analyse : Anticorps antiviraux.
- effets indésirables : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- pharmacologie : Sialidase.
- Adolescent, Calendrier vaccinal, Enfant, Enfant d'âge préscolaire, Humains, Nourrisson, Tests d'inhibition de l'hémagglutination.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , analysis : Antibodies, Viral.
- chemical , immunology : Influenza Vaccines.
- chemical , pharmacology : Neuraminidase.
- Adolescent, Child, Child, Preschool, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Infant.
Abstract
In a group of 144 children (six months to 15 years) three doses vaccine were administered. The latter contains the main strains of the influenza type A and strain type B. From the clinical evaluation ensued that this vaccine in children is areactogenic even after repeated doses. The morbidity was followed up for 18 months and during this period in the immunized communities no case of influenza was recorded. The antibody levels were assessed by the haemagglutination-inhibition test (HIT) and the enzyme test (NIT) The assessed HI titres were high after the second and third dose, in particular as regard subtype H3N2 and H1N1. The titres against subtype H2N2 and type B were markedly lower. Antibodies against neuraminidase were highest against subtype N1 and type B, lowest against N2. The dynamics of the formation of antineuraminidase antibodies was similar as that of haemagglutination-inhibition antibodies. Based on these results the vaccine is evaluated as very satisfactory and after approval by the Ministry of Health and Social Affairs this vaccine will be used for a field trial in 1-2 thousand children where above all the protective effect of the vaccine will be investigated. This vaccine is intended for children, with the aim to induce complex immunity against influenza.
PubMed: 2289253
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000452
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000452
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000402
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000803
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000803
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000803
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002163
Links to Exploration step
pubmed:2289253Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Reactivity and immunologic activity of polyvalent split influenza vaccine in children].</title>
<author><name sortKey="Zavadova, H" sort="Zavadova, H" uniqKey="Zavadova H" first="H" last="Závadová">H. Závadová</name>
<affiliation wicri:level="3"><nlm:affiliation>Ustav sér a ockovacích látek, Praha.</nlm:affiliation>
<country>République tchèque</country>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
<wicri:orgArea>Ustav sér a ockovacích látek</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Domorazkova, E" sort="Domorazkova, E" uniqKey="Domorazkova E" first="E" last="Domorázková">E. Domorázková</name>
</author>
<author><name sortKey="Skovrankova, J" sort="Skovrankova, J" uniqKey="Skovrankova J" first="J" last="Skovránková">J. Skovránková</name>
</author>
<author><name sortKey="Vodickova, M" sort="Vodickova, M" uniqKey="Vodickova M" first="M" last="Vodicková">M. Vodicková</name>
</author>
<author><name sortKey="Ragac, P" sort="Ragac, P" uniqKey="Ragac P" first="P" last="Ragac">P. Ragac</name>
</author>
<author><name sortKey="Vonka, V" sort="Vonka, V" uniqKey="Vonka V" first="V" last="Vonka">V. Vonka</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2289253</idno>
<idno type="pmid">2289253</idno>
<idno type="wicri:Area/PubMed/Corpus">000452</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000452</idno>
<idno type="wicri:Area/PubMed/Curation">000452</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000452</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000402</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000402</idno>
<idno type="wicri:Area/Ncbi/Merge">000803</idno>
<idno type="wicri:Area/Ncbi/Curation">000803</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000803</idno>
<idno type="wicri:doubleKey">0069-2328:1990:Zavadova H:reactivity:and:immunologic</idno>
<idno type="wicri:Area/Main/Merge">002163</idno>
<idno type="wicri:Area/Main/Curation">002064</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Reactivity and immunologic activity of polyvalent split influenza vaccine in children].</title>
<author><name sortKey="Zavadova, H" sort="Zavadova, H" uniqKey="Zavadova H" first="H" last="Závadová">H. Závadová</name>
<affiliation wicri:level="3"><nlm:affiliation>Ustav sér a ockovacích látek, Praha.</nlm:affiliation>
<country>République tchèque</country>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
<wicri:orgArea>Ustav sér a ockovacích látek</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Domorazkova, E" sort="Domorazkova, E" uniqKey="Domorazkova E" first="E" last="Domorázková">E. Domorázková</name>
</author>
<author><name sortKey="Skovrankova, J" sort="Skovrankova, J" uniqKey="Skovrankova J" first="J" last="Skovránková">J. Skovránková</name>
</author>
<author><name sortKey="Vodickova, M" sort="Vodickova, M" uniqKey="Vodickova M" first="M" last="Vodicková">M. Vodicková</name>
</author>
<author><name sortKey="Ragac, P" sort="Ragac, P" uniqKey="Ragac P" first="P" last="Ragac">P. Ragac</name>
</author>
<author><name sortKey="Vonka, V" sort="Vonka, V" uniqKey="Vonka V" first="V" last="Vonka">V. Vonka</name>
</author>
</analytic>
<series><title level="j">Ceskoslovenska pediatrie</title>
<idno type="ISSN">0069-2328</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Antibodies, Viral (analysis)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Infant</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Neuraminidase (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Anticorps antiviraux (analyse)</term>
<term>Calendrier vaccinal</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Humains</term>
<term>Nourrisson</term>
<term>Sialidase (pharmacologie)</term>
<term>Tests d'inhibition de l'hémagglutination</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Sialidase</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Infant</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Calendrier vaccinal</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Humains</term>
<term>Nourrisson</term>
<term>Tests d'inhibition de l'hémagglutination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In a group of 144 children (six months to 15 years) three doses vaccine were administered. The latter contains the main strains of the influenza type A and strain type B. From the clinical evaluation ensued that this vaccine in children is areactogenic even after repeated doses. The morbidity was followed up for 18 months and during this period in the immunized communities no case of influenza was recorded. The antibody levels were assessed by the haemagglutination-inhibition test (HIT) and the enzyme test (NIT) The assessed HI titres were high after the second and third dose, in particular as regard subtype H3N2 and H1N1. The titres against subtype H2N2 and type B were markedly lower. Antibodies against neuraminidase were highest against subtype N1 and type B, lowest against N2. The dynamics of the formation of antineuraminidase antibodies was similar as that of haemagglutination-inhibition antibodies. Based on these results the vaccine is evaluated as very satisfactory and after approval by the Ministry of Health and Social Affairs this vaccine will be used for a field trial in 1-2 thousand children where above all the protective effect of the vaccine will be investigated. This vaccine is intended for children, with the aim to induce complex immunity against influenza.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002064 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002064 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:2289253 |texte= [Reactivity and immunologic activity of polyvalent split influenza vaccine in children]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:2289253" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |